Logo

GELS

Gelteq Limited Ordinary Shares

GELS

Gelteq Limited Ordinary Shares • NASDAQ
$1.08 ▲ 1.89% (+0.02)
Market Cap $10.19 M
52w High $5.50
52w Low $0.77
Dividend Yield 0%
P/E -2.3
Volume 119.88K
Outstanding Shares 9.44M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $0 $966.555K ▼ $-1.133M ▼ 0% $0 $-679.856K ▼
Q3-2024 $0 ▲ $10.097M ▲ $-727.419K ▲ 0% ▼ $0 $-279.744K ▲
Q4-2023 $-1 ▼ $833.354K ▼ $-947.83K ▲ 94.783M% ▲ $0 ▲ $-527.688K ▲
Q4-2022 $147.536K ▲ $1.189M ▲ $-1.237M ▼ -838.209% ▼ $-0.131 ▼ $-829.366K ▼
Q4-2021 $0 $391.986K $-233.414K 0% $-0.025 $-335.831K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $3.047M ▲ $25.115M ▲ $6.322M ▲ $18.794M ▲
Q4-2024 $24.522K ▼ $20.758M ▼ $5.646M ▲ $15.112M ▼
Q3-2024 $145.861K ▼ $21.224M ▼ $4.979M ▲ $16.245M ▼
Q4-2023 $399.224K ▲ $22.495M ▲ $3.836M ▲ $18.658M ▼
Q3-2023 $119.119K $22.36M $2.754M $19.606M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-1.133M ▼ $-302.15K ▲ $-65.06K ▼ $248.54K ▼ $-121.339K ▼ $-367.21K ▼
Q3-2024 $0 $-339.149K ▼ $-3.149K ▲ $358.706K ▼ $19.077K ▼ $-342.298K ▲
Q4-2023 $0 $0 $-15.727K ▼ $748.229K ▲ $280.105K ▲ $-465.263K ▲
Q4-2022 $0 $0 $0 ▼ $-6K ▼ $-657.619K ▼ $-652.636K ▼
Q4-2021 $0 $0 $138.894K $200 $18.172K $-120.922K

Five-Year Company Overview

Income Statement

Income Statement GELS is essentially a pre‑revenue story at this stage. The company has not yet generated meaningful sales, and past results show ongoing accounting losses typical of an early‑stage healthcare platform building out its technology and relationships. There is no visible profit engine yet; the investment case today is almost entirely about future potential commercialisation rather than current earnings power. Until products are approved, partnered, and on the market, the income statement is likely to remain loss‑making and quite sensitive to R&D and overhead spending decisions.

Balance Sheet

Balance Sheet The balance sheet looks very small and simple: modest assets, funded mainly by equity, and no notable debt. That means low financial leverage but also a very limited capital base to fund ambitious growth on its own. The absence of clear cash balances and the small scale suggest that the company will probably rely heavily on fresh capital from markets or partners to advance its platform. Financial resilience will depend less on existing resources and more on the company’s ability to keep attracting external funding on reasonable terms.

Cash Flow

Cash Flow Reported cash flow figures are effectively flat, reinforcing the picture of a business that is still at the build‑out and validation stage rather than active commercial operations. With no operating cash inflow and no visible investment outlays in the data presented, investors should assume that future periods will likely involve increased cash burn as trials, regulatory work, and commercial partnerships ramp up. The key cash‑flow question is not optimisation of current cash, but whether the company can time new funding rounds and partner contributions to cover that expected burn without overly diluting existing shareholders.

Competitive Edge

Competitive Edge GELS is positioning itself as a specialist drug‑delivery platform rather than a traditional drug maker. Its patented gel technology targets real pain points: difficulty swallowing pills, poor drug absorption, and unpleasant taste. The business‑to‑business, white‑label model lets larger partners handle branding and distribution, which can be an efficient way to scale if those partners commit volume. Manufacturing and distribution tie‑ups in Australia and North America strengthen credibility and operational capacity. On the other hand, GELS is tiny relative to established pharma and generic companies, depends heavily on partner adoption, and still needs clinical and regulatory milestones to fully prove its edge. The moat today rests more on intellectual property and technical promise than on entrenched market share.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the story. GELS is building a flexible gel platform that can improve how a wide range of drugs and nutrients are delivered and absorbed. Early preclinical work suggests it can meaningfully boost absorption for at least one existing medicine, and the technology is being tested on harder‑to‑deliver, poorly soluble drugs where the need is significant. The company is also exploring specific medical applications, such as a compound aimed at reducing bowel polyp growth, and broadening into nutraceuticals, sports nutrition, and animal health. Collaborations with universities and healthcare partners support this R&D push. The upside is a diverse pipeline and multiple ways to win; the risk is that many of these programs are early, subject to scientific, regulatory, and commercial uncertainty, and will take years to fully validate.

Summary

GELS is an early‑stage healthcare platform company whose current profile is driven far more by its technology and partnerships than by its financial statements. It has no established revenue base yet, a very small but clean balance sheet, and cash dynamics that will likely involve ongoing burn and the need for outside capital. In return for that financial immaturity, investors get exposure to a patented oral gel delivery platform that could be applied across pharmaceuticals, over‑the‑counter products, nutraceuticals, and animal health, supported by a B2B model and initial manufacturing and distribution partnerships. The opportunity is in scaling this platform, securing regulatory approvals, and converting scientific promise into recurring, diversified revenue streams. The main risks lie in execution, regulatory outcomes, partner uptake, and the company’s ability to finance its long development path without undue strain. Overall, GELS currently resembles a high‑innovation, high‑uncertainty story rather than a mature, cash‑generating healthcare business.

NEWS

November 24, 2025 · 8:30 AM UTC

Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

Read more

November 14, 2025 · 4:10 PM UTC

Healthy Extracts Reports Record Q3 2025, with Revenue up 23%

Read more

November 11, 2025 · 8:35 AM UTC

Nutraceutical Technology Leader, Healthy Extracts, Invited to Present at the Trickle Research Microcap Conference on November 13, 2025

Read more

September 12, 2025 · 7:30 AM UTC

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Read more

September 5, 2025 · 11:26 AM UTC

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Read more